Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-019-02298-9
Abstract: BackgroundCheckpoint inhibitors are first-line therapies in melanoma, but safety in older adults has not yet been assessed. Ipilimumab improves survival, but immunologic-related adverse events (AEs) can be threatening, and its use in elderly people raises… read more here.
Keywords: melanoma; treated ipilimumab; elderly patients; years treated ... See more keywords
Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI)
Sign Up to like & getrecommendations! Published in 2020 at "Oncoimmunology"
DOI: 10.1080/2162402x.2020.1846914
Abstract: ABSTRACT Background: The gut microbiota has a key role in the regulation of the immune system. Disruption of the gut microbiota’s composition by antibiotics might significantly affect the efficacy of immune checkpoint inhibitors. In a… read more here.
Keywords: patients treated; 1585 patients; treated ipilimumab; hospital ... See more keywords